LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 204

Search options

  1. Article ; Online: Current Perspectives of Pharmacotherapies for COPD.

    Pleasants, Roy A / Donohue, James F

    Respiratory care

    2023  Volume 68, Issue 7, Page(s) 927–938

    Abstract: Pharmacotherapies and avoidance of environmental/inhaled toxins are core to managing COPD. Compared to the drugs available 50 years ago, there has been substantial progress with COPD pharmacotherapies, but gaps in adherence and inhaler use persist. ... ...

    Abstract Pharmacotherapies and avoidance of environmental/inhaled toxins are core to managing COPD. Compared to the drugs available 50 years ago, there has been substantial progress with COPD pharmacotherapies, but gaps in adherence and inhaler use persist. Personalizing inhaled pharmacotherapies is now possible with digital technologies by objectively documenting adherence and guiding inhaler technique. Another means to improve existing pharmacotherapies is through phenotyping and biomarkers. This is especially important considering the heterogeneity of the disease COPD. Blood eosinophils are now a recommended biomarker to guide use of inhaled corticosteroids and biologics in COPD. On the near horizon, we will see new inhaled medications as dual phosphodiesterase inhibitors, drugs to treat basic protein abnormalities as in alpha-1 antitrypsin deficiency that could have remarkable benefits, and biologic drugs targeting specific cell/mediator types in the COPD population. Characterization of COPD phenotypes, as asthma/COPD overlap and comorbid heart disease are vital to understand how to optimize pharmacotherapies. Importantly, we must determine how to optimize current medications; otherwise, we will repeat the same mistakes with new medications. But as we know so well, as we peel one layer of complexity, we encounter many more questions, all the while dedicated to limiting the burden of COPD.
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Bronchodilator Agents/therapeutic use ; Administration, Inhalation ; Nebulizers and Vaporizers ; Adrenal Cortex Hormones/therapeutic use
    Chemical Substances Bronchodilator Agents ; Adrenal Cortex Hormones
    Language English
    Publishing date 2023-06-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603252-7
    ISSN 1943-3654 ; 0098-9142 ; 0020-1324
    ISSN (online) 1943-3654
    ISSN 0098-9142 ; 0020-1324
    DOI 10.4187/respcare.10952
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2285: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Response to Letter to the Editor: Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.

    Donohue, James F

    Respiratory medicine

    2016  Volume 110, Page(s) 81

    MeSH term(s) Benzyl Alcohols/administration & dosage ; Chlorobenzenes/administration & dosage ; Female ; Fluticasone-Salmeterol Drug Combination/administration & dosage ; Forced Expiratory Volume/drug effects ; Humans ; Male ; Pulmonary Disease, Chronic Obstructive/drug therapy
    Chemical Substances Benzyl Alcohols ; Chlorobenzenes ; Fluticasone-Salmeterol Drug Combination
    Language English
    Publishing date 2016-01
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2015.11.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui III Zs.19: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Another Choice for Prevention of COPD Exacerbations.

    Donohue, James F

    The New England journal of medicine

    2016  Volume 374, Issue 23, Page(s) 2284–2286

    MeSH term(s) Adrenergic beta-2 Receptor Agonists/therapeutic use ; Female ; Fluticasone-Salmeterol Drug Combination/therapeutic use ; Glucocorticoids/therapeutic use ; Glycopyrrolate/therapeutic use ; Humans ; Indans/therapeutic use ; Male ; Muscarinic Antagonists/therapeutic use ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Quinolones/therapeutic use
    Chemical Substances Adrenergic beta-2 Receptor Agonists ; Fluticasone-Salmeterol Drug Combination ; Glucocorticoids ; Indans ; Muscarinic Antagonists ; Quinolones ; indacaterol (8OR09251MQ) ; Glycopyrrolate (V92SO9WP2I)
    Language English
    Publishing date 2016-06-09
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMe1604444
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.34: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.

    Donohue, James F / Rheault, Tara / MacDonald-Berko, Margot / Bengtsson, Thomas / Rickard, Kathleen

    International journal of chronic obstructive pulmonary disease

    2023  Volume 18, Page(s) 1611–1622

    Abstract: Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 ... ...

    Abstract Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.
    MeSH term(s) Humans ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/chemically induced ; Quality of Life ; Phosphodiesterase 4 Inhibitors ; Isoquinolines/pharmacology ; Administration, Inhalation ; Bronchodilator Agents
    Chemical Substances ensifentrine (3E3D8T1GIX) ; Phosphodiesterase 4 Inhibitors ; Isoquinolines ; Bronchodilator Agents
    Language English
    Publishing date 2023-07-28
    Publishing country New Zealand
    Document type Journal Article ; Review
    ZDB-ID 2212419-6
    ISSN 1178-2005 ; 1176-9106
    ISSN (online) 1178-2005
    ISSN 1176-9106
    DOI 10.2147/COPD.S413436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Low Doses of Long-Acting β-Agonists/Long-Acting Muscarinic Agents with Large Effects. The FLIGHT Study.

    Donohue, James F

    American journal of respiratory and critical care medicine

    2015  Volume 192, Issue 9, Page(s) 1028–1030

    MeSH term(s) Female ; Glycopyrrolate/analogs & derivatives ; Glycopyrrolate/therapeutic use ; Humans ; Indans/therapeutic use ; Male ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Quinolones/therapeutic use
    Chemical Substances Indans ; Quinolones ; Glycopyrrolate (V92SO9WP2I)
    Language English
    Publishing date 2015-11-01
    Publishing country United States
    Document type Comment ; Journal Article
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.201507-1442ED
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: FEV

    Crim, Courtney / Frith, Lucy J / Midwinter, Dawn / Donohue, James F

    American journal of respiratory and critical care medicine

    2021  Volume 203, Issue 12, Page(s) 1573–1576

    MeSH term(s) Aged ; Female ; Forced Expiratory Volume ; Humans ; Male ; Middle Aged ; Pulmonary Disease, Chronic Obstructive/therapy ; Symptom Assessment/methods ; Symptom Assessment/statistics & numerical data
    Language English
    Publishing date 2021-03-01
    Publishing country United States
    Document type Comparative Study ; Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202012-4322LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Systematic review comparing LABA, olodaterol, and indacaterol: limitations.

    Donohue, James F

    International journal of chronic obstructive pulmonary disease

    2014  Volume 9, Page(s) 1331–1333

    MeSH term(s) Adrenergic beta-2 Receptor Agonists/administration & dosage ; Benzoxazines/administration & dosage ; Bronchodilator Agents/administration & dosage ; Humans ; Indans/administration & dosage ; Lung/drug effects ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Quinolones/administration & dosage
    Chemical Substances Adrenergic beta-2 Receptor Agonists ; Benzoxazines ; Bronchodilator Agents ; Indans ; Quinolones
    Language English
    Publishing date 2014
    Publishing country New Zealand
    Document type Comment ; Letter
    ISSN 1178-2005
    ISSN (online) 1178-2005
    DOI 10.2147/COPD.S74766
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  8. Article ; Online: An Update on the Global Initiative for Chronic Obstructive Lung Disease 2017 Guidelines With a Focus on Classification and Management of Stable COPD.

    Burkes, Robert M / Donohue, James F

    Respiratory care

    2018  Volume 63, Issue 6, Page(s) 749–758

    Abstract: The 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines offer important changes to the assessment and management of stable COPD of importance to practitioners, respiratory therapists, pharmacists, and nurses who care for ... ...

    Abstract The 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines offer important changes to the assessment and management of stable COPD of importance to practitioners, respiratory therapists, pharmacists, and nurses who care for patients with COPD. Therapies are now chosen based on the burden of symptoms and the history of COPD exacerbations, and inhaler regimens are modifiable based on continual clinical reassessment. Although identifying the degree of airway obstruction remains important for informing the clinical status of the patient with COPD, FEV
    MeSH term(s) Administration, Inhalation ; Bronchodilator Agents/therapeutic use ; Forced Expiratory Volume ; Humans ; Practice Guidelines as Topic ; Pulmonary Disease, Chronic Obstructive/diagnosis ; Pulmonary Disease, Chronic Obstructive/therapy ; Severity of Illness Index
    Chemical Substances Bronchodilator Agents
    Language English
    Publishing date 2018-05-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 603252-7
    ISSN 1943-3654 ; 0098-9142 ; 0020-1324
    ISSN (online) 1943-3654
    ISSN 0098-9142 ; 0020-1324
    DOI 10.4187/respcare.06174
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 2285: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Improvements in health status with revefenacin, a once-daily, nebulized, long-acting muscarinic antagonist for chronic obstructive pulmonary disease.

    Donohue, James F / Ferguson, Gary T / Ohar, Jill A / Lombardi, David A / Schneider, Roslyn F / Johnson, Karmon

    Respiratory medicine

    2023  Volume 208, Page(s) 107123

    Abstract: Background: Replicate, 12-week, phase 3 trials (0126 and 0127) of once-daily nebulized revefenacin 175 μg vs placebo demonstrated significant bronchodilation and improvements in health status in patients with moderate to very severe chronic obstructive ... ...

    Abstract Background: Replicate, 12-week, phase 3 trials (0126 and 0127) of once-daily nebulized revefenacin 175 μg vs placebo demonstrated significant bronchodilation and improvements in health status in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). This post hoc analysis evaluated improvement in patient-reported outcomes (PROs), including the St. George's Respiratory Questionnaire (SGRQ), COPD Assessment Test (CAT), and Clinical COPD Questionnaire (CCQ) in both women and men.
    Methods: Participants were pooled from the two 12-week studies (411 [51%] women and 401 [49%] men). Changes in PROs were assessed overall and separately in men and women.
    Results: Revefenacin improved SGRQ and CAT total scores from baseline in both studies; improvement in CCQ total score reached significance only in 0126. In pooled data, a greater proportion of patients achieved clinically meaningful response in SGRQ score (≥4-unit decrease from baseline) with revefenacin vs placebo (odds ratio, 1.5; 95% confidence interval, 1.1-2.1; P = 0.012). Clinically meaningful responses were also seen in CAT (≥2-unit decrease from baseline) and CCQ (≥0.4-unit decrease from baseline) scores with revefenacin vs placebo. When stratified by sex, improvements from baseline in SGRQ, CAT, and CCQ scores following revefenacin vs placebo reached statistical significance only in women.
    Conclusions: Maintenance treatment with revefenacin improved health status in patients with moderate to very severe COPD; however, the effect was more pronounced for women than men.
    Clinicaltrials: GOV: NCT02459080; NCT02512510.
    MeSH term(s) Female ; Humans ; Male ; Benzamides ; Bronchodilator Agents/therapeutic use ; Forced Expiratory Volume ; Health Status ; Muscarinic Antagonists ; Pulmonary Disease, Chronic Obstructive
    Chemical Substances Benzamides ; Bronchodilator Agents ; Muscarinic Antagonists ; revefenacin (G2AE2VE07O)
    Language English
    Publishing date 2023-01-18
    Publishing country England
    Document type Clinical Trial, Phase III ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1003348-8
    ISSN 1532-3064 ; 0954-6111
    ISSN (online) 1532-3064
    ISSN 0954-6111
    DOI 10.1016/j.rmed.2023.107123
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ui III Zs.19: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Pharmacotherapy for Chronic Obstructive Pulmonary Disease: Molecules and Delivery Are Equally Important.

    Mahler, Donald A / Ohar, Jill A / Ferguson, Gary T / Donohue, James F

    American journal of respiratory and critical care medicine

    2020  Volume 202, Issue 10, Page(s) 1482

    MeSH term(s) Bronchodilator Agents/therapeutic use ; Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; United States
    Chemical Substances Bronchodilator Agents
    Language English
    Publishing date 2020-09-17
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.202004-1489LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh II Zs.80: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top